|Bid||361.00 x 100|
|Day's Range||500.75 - 518.00|
|52 Week Range||325.35 - 543.55|
|PE Ratio (TTM)||62.12|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Neothetics, Inc. (NEOT) announced disappointing top line results from a phase II proof-of-concept study, LIPO-202-CL-31, evaluating its lead candidate, LIPO-202, for reduction of submental subcutaneous fat.
Esperion Therapeutics, Inc. (ESPR) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Zetia (10 mg) for an LDL-C lowering indication.
Strongbridge Biopharma plc (SBBP) moved big last session, as the company saw its shares rise over 10% on the day.